|
Volumn 93, Issue 3, 2015, Pages 725-726
|
In Reply to Adams and Kwee
a b c b |
Author keywords
[No Author keywords available]
|
Indexed keywords
BLEOMYCIN;
CYCLOPHOSPHAMIDE;
DACARBAZINE;
DOXORUBICIN;
ETOPOSIDE;
FLUORODEOXYGLUCOSE;
PREDNISONE;
PROCARBAZINE;
VINBLASTINE;
VINCRISTINE;
ANTINEOPLASTIC AGENT;
FLUORODEOXYGLUCOSE F 18;
RADIOPHARMACEUTICAL AGENT;
CANCER CHEMOTHERAPY;
CANCER PATIENT;
CANCER RADIOTHERAPY;
CANCER RECURRENCE;
CANCER STAGING;
COHORT ANALYSIS;
EARLY CANCER;
HODGKIN DISEASE;
HUMAN;
LETTER;
MULTIPLE CYCLE TREATMENT;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PATIENT RISK;
POSITRON EMISSION TOMOGRAPHY;
PREDICTIVE VALUE;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
SALVAGE THERAPY;
FEMALE;
MALE;
PROCEDURES;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
FEMALE;
FLUORODEOXYGLUCOSE F18;
HODGKIN DISEASE;
HUMANS;
MALE;
POSITRON-EMISSION TOMOGRAPHY;
RADIOPHARMACEUTICALS;
|
EID: 84942358020
PISSN: 03603016
EISSN: 1879355X
Source Type: Journal
DOI: 10.1016/j.ijrobp.2015.07.003 Document Type: Letter |
Times cited : (2)
|
References (6)
|